Sharon Rosenzweig-Lipson

Sharon Rosenzweig-Lipson, Ph.D., has served as the Vice President of Research and Development since 2011. She has a leading role in the HOPE4MCI clinical-stage program and heads the AgeneBio development of novel neurotherapeutics in the selective GABA alpha5 positive allosteric modulator program.

Dr. Rosenzweig-Lipson’s work with AgeneBio has been integral to the AGB101 clinical program. She led the development of the proprietary formulation of AGB101, management of Phase 1 with FDA review, and completed the manufacture of medical supplies for the Phase 3 program. She is currently the Project Director of the HOPE4MCI clinical program. She also leads the GABA-A a5 PAM discovery program and manages the Blueprint collaboration (government, academic, CRO). Dr. Rosenzweig-Lipson brings expertise in screening strategies, in vivo models, translation, and clinical development strategies with more than 25 years of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry. She spent her career focused on psychiatric and neurologic indications in the industry, including American Cyanamid, American Home Products, Wyeth, and Pfizer. She led numerous drug discovery and drug development teams from the earliest exploratory stages through a successful Phase 2 Proof of Concept in Schizophrenia. She earned her Ph.D. in Behavioral Neuroscience from Harvard University.